NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

LC. You've got it! Yes, the results of the Ph III trial for DCVax-L actually showed exactly what you sugges:

LC:

Something never really discussed but always bothered me a bit is IF DCVAX-L was truly efficacious, why the need to remove as much tumor as possible? Wouldn’t it be better to leave the periphery alone so as not to accidentally cause more damage?

If you go back and read over the JAMA published results of our trial, you'll see that patients who did not have a high level of resection of their tumor did surprisingly well, much better than in past trials for GBM. I think you can also find this in Dr. Bosch's powerpoint notes. In fact its everywhere in articles about the trial. It was widely discussed here, there, everywhere. I'll let you look it up. It's hard not to stumble over the discussions. There's also nicely done graphs that don't involve a lot of words that get the point across...that DCVax-L works very well on patients whose resections were not even near complete.